The earnings call reflected a generally positive outlook with strong financial performance and significant advancements in pharmaceuticals and pipeline developments, despite challenges in the Diagnostics segment and market uncertainties.

Company Guidance

During the call, Roche provided extensive guidance on its financial and operational performance. The company reported a 7% increase in group sales, driven primarily by a 10% growth in the Pharmaceuticals division, which further accelerated to 11% in Q2. Core operating profit rose by 11%, leading to a 1.1 percentage point increase in the core operating margin, while core EPS grew by 12%. The Diagnostics division remained flat due to the impact of China’s healthcare pricing reforms; however, without these, it would have grown by 6%. Roche revised its full-year LOE impact guidance from CHF 1.2 billion to CHF 1 billion. Significant product milestones included the EU approval of Itovebi and U.S. approval of Susvimo. The company highlighted strong momentum in its product portfolio, with Vabysmo growing by 18% and Xolair serving over 60,000 patients in the U.S. Roche also emphasized its strategic focus on R&D efficiency, resulting in cost savings of CHF 1 billion and a target of CHF 3 billion by 2030. The call concluded with a reaffirmation of Roche's conservative financial guidance, citing geopolitical uncertainties, and a promise to deliver consistent performance.

Strong Overall Financial Performance

The group sales increased by 7%, with Pharmaceuticals growing by 10%, and core operating profit growing by 11%. Core EPS grew by 12%.

Pharmaceutical Achievements

Pharmaceutical segment showed strong growth with key products like Phesgo and Xolair driving a significant portion of the increase, including a 55% growth for Phesgo.

Pipeline Development

Progress in the pipeline with 4 medicines moving into Phase III, including promising developments in Parkinson's disease and a potential new antibiotic for gram-negative bacteria.

Diagnostics Regulatory Approvals

Diagnostics division received two approvals and is preparing for the launch of a new sequencing solution expected to be disruptive in terms of throughput, cost, and accuracy.

Roche Holding Ltd (CH:RO) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

CH:RO Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Jan 29, 2026	2025 (Q4)	8.57 / -	8.57	―	―	―
Jul 24, 2025	2025 (Q2)	10.77 / 11.08	10.23	8.31% (+0.85)	―	―
Jan 30, 2025	2024 (Q4)	8.12 / 8.57	8.47	1.18% (+0.10)	―	―
Jul 25, 2024	2024 (Q2)	9.37 / 10.23	34.746	-70.56% (-24.52)	―	―
Feb 01, 2024	2023 (Q4)	8.37 / 8.47	8.27	2.42% (+0.20)	―	―
Jul 27, 2023	2023 (Q2)	10.15 / 34.75	11.76	195.46% (+22.99)	―	―
Feb 02, 2023	2022 (Q4)	8.64 / 8.27	9.25	-10.59% (-0.98)	―	―
Jul 21, 2022	2022 (Q2)	11.09 / 11.76	10.56	11.36% (+1.20)	―	―
Feb 03, 2022	2021 (Q4)	9.54 / 9.25	8.71	6.20% (+0.54)	―	―
Jul 22, 2021	2021 (Q2)	8.06 / 10.56	10.44	1.15% (+0.12)	―	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

CH:RO Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Jul 24, 2025	CHF277.00	CHF280.40	+1.23%
Jan 30, 2025	CHF290.35	CHF294.81	+1.54%
Jul 25, 2024	CHF287.44	CHF295.78	+2.90%
Feb 01, 2024	CHF244.32	CHF230.50	-5.66%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Roche Holding Ltd (CH:RO) report earnings?

Roche Holding Ltd (CH:RO) is schdueled to report earning on Jan 29, 2026, Before Open (Confirmed).

What is Roche Holding Ltd (CH:RO) earnings time?

Roche Holding Ltd (CH:RO) earnings time is at Jan 29, 2026, Before Open (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is the P/E ratio of Roche Holding Ltd stock?

The P/E ratio of Roche Holding Ltd is N/A.

What is CH:RO EPS forecast?

CH:RO EPS forecast for the fiscal quarter 2025 (Q4) is 8.58.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing